Last updated: 07/17/2024 16:50:09
4 week switch study in hemodialysis-dependent subjects with anemia associated with chronic kidney disease
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease
Trial description: This is a four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from stable rhEPO to GSK1278863 in approximately 68 hemodialysis-dependent subjects with anemia associated with chronic kidney disease. The study consists of a screening phase of 2 weeks, a 4-week treatment phase and a 2-week follow-up phase. The range of Hgb values for study eligibility is 9.5-12.0 g/dL and the subjects must have received the same rhEPO product with total weekly doses that varied by no more than 50% during the 4 weeks prior to the Screening visit (Week -1. This study aims to estimate the relationship between dose of GSK1278863 and Hgb response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease after switching from a stable maintenance dose of recombinant human erythropoetin (rhEPO).
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Modeled Hemoglobin (Hgb) change from Baseline (pre-dose on Day 1) at 4 weeks of treatment
Timeframe: Baseline (pre-dose on Day 1) and up to week 4
Secondary outcomes:
Hgb variability over 4 weeks
Timeframe: Up to 4 weeks
Evaluation of change from Baseline in hepcidin over period
Timeframe: Baseline (pre-dose on Day 1) and up to 4 weeks
Evaluation of change from Baseline (pre-dose on Day 1) in high sensitivity C-Reactive Protein (hsCRP) over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and up to 4 weeks
Change from Baseline for erythropoeitin (EPO) over period
Timeframe: Baseline (pre-dose on Day 1) and up to 4 weeks
Evaluation of change from Baseline (pre-dose on Day 1) for peak Vascular endothelial growth factor (VEGF) over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and up to 4 weeks
Evaluation of change from Baseline (Pre-dose on Day 1) for hematocrit over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and up to 4 weeks
Residual standard deviation in Hgb (from the linear regression)
Timeframe: Up to 4 weeks
Number of days spent within Hgb range ( ±0.5 g/dL and ±1 g/dL ) from Baseline Hgb
Timeframe: Baseline (pre-dose on Day 1) and up to 4 weeks
Evaluation of change from Baseline (pre-dose on Day 1) in ferritin over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and Week 4
Evaluation of change from Baseline (pre-dose on Day 1) for transferrin over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and Week 4
Change from Baseline (pre-dose on Day 1) for transferrin saturation over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and Week 4
Change from Baseline (pre-dose on Day 1) for total iron over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and at Week 4
Change from Baseline (pre-dose on Day 1) in total iron binding capacity over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and Week 4
Change from Baseline (pre-dose on Day 1) for red blood cells (RBCs) over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and up to 4 weeks
Change from Baseline (pre-dose on Day 1) for reticulocytes over 4 weeks
Timeframe: Baseline (pre-dose on Day 1) and up to 4 weeks
Number of participants reaching Hgb stopping criteria
Timeframe: Up to 4 weeks
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Timeframe: Up to 4 weeks
Number of participants discontinuing the study treatment due to AEs
Timeframe: Up to 4 weeks
Mean plasma concentration of GSK1278863 and GSK1278863 metabolites over 4 weeks
Timeframe: Up to 4 weeks
Number of participants with abnormal hematology and clinical chemistry parameters of potential clinical concern (PCI)
Timeframe: Up to 6 weeks (including follow-up)
Number of participants with abnormal vital signs of PCI
Timeframe: Up to 6 weeks
Number of participants with electrocardiogram (ECG) findings over period
Timeframe: Up to 6 weeks
Interventions:
Drug: GSK1278863
Drug: rhEPO
Enrollment:
86
Observational study model:
Not applicable
Primary completion date:
2013-27-05
Time perspective:
Not applicable
Clinical publications:
Louis Holdstock, Amy M. Meadowcroft, Rayma Maier, Brendan M. Johnson, Delyth Jones, Anjay Rastogi, Steven Zeig,, John J. Lepore, Alexander R. Cobitz .Four-week studies of oral HIF-prolyl hydroxylase inhibitor GSK1278863 for Treatment of Anemia .J Am Soc Nephrol.2016;April(27):1234-44
Medical condition
Anaemia
Product
daprodustat
Collaborators
Pharmaceutical Product Development Clinical Research Organization (CRO)
Study date(s)
May 2012 to May 2013
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 99 years
Accepts healthy volunteers
No
- 1. Age and weight: >/=18 years of age and >/=45 kg (weight post-dialysis).
- 2. On three times weekly hemodialysis for at least 8 weeks, irrespective of eGFR values and stage of chronic kidney disease (CKD).
- 1. Dialysis modality: On peritoneal dialysis OR planned change in dialysis modality within the study time period.
- 2. rhEPO Hyporesponders: As defined by an epoetin dose of >/=360 IU/kg/week IV or darbepoetin dose of >/=1.8 µg/kg/week IV within the prior 8 weeks.
Inclusion and exclusion criteria
Inclusion criteria:
- 1. Age and weight: >/=18 years of age and >/=45 kg (weight post-dialysis). 2. On three times weekly hemodialysis for at least 8 weeks, irrespective of eGFR values and stage of chronic kidney disease (CKD). 3. A single-pool Kt/Vurea of >/=1.2 based on a historical value obtained within the prior month in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio (URR) of at least 65%. 4. rhEPO use: Using the same rhEPO (epoetins or darbepoetin) with total weekly doses that varied by no more than 50% during the prior 4 weeks (i.e., maximum vs. minimum total weekly doses /= 2.0 ng/mL (may rescreen in one month). 8. Ferritin: >/=40 ng/mL with the absence of microcytic or hypochromic RBCs. 9. Transferrin saturation (TSAT): Within the reference range. 10. Iron replacement therapy: Stable maintenance dose of oral iron replacement therapy, if required, that will be maintained throughout the study. NOTE: IV iron replacement therapy is not allowed the two weeks prior to Screening through the end of the study (Week 6). 11. QTc: QTcB <470 msec or QTcB <480 msec in subjects with bundle branch block obtained at Screening Visit (based on Central Reader’s interpretation). 12. Females: Eligible to participate if she is of childbearing potential, and must agree to use one of the approved contraception methods from Screening until completion of the Follow-up Visit OR of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation of hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH)>40MIU/ml and estradiol <40pg/ml is confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. 13. Males: Must agree to use one of the approved contraceptive methods from the time of Screening until completion of the Follow-up Visit.
Exclusion criteria:
- 1. Dialysis modality: On peritoneal dialysis OR planned change in dialysis modality within the study time period. 2. rhEPO Hyporesponders: As defined by an epoetin dose of >/=360 IU/kg/week IV or darbepoetin dose of >/=1.8 µg/kg/week IV within the prior 8 weeks. 3. Renal transplant: Renal transplant anticipated or scheduled within the study time period or subjects with a functioning renal transplant. 4. Mircera or Peginesatide: Current or prior use (within the prior 8 weeks) of Mircera (methoxy polyethylene glycol epoetin beta) OR peginesatide. 5. Total CPK: >5x the upper limit of the reference range. 6. HIV: Positive HIV antibody. 7. History of myocardial infarction or acute coronary syndrome within the prior 6 months. 8. History of stroke or transient ischemic attacks (TIAs) within the prior 6 months. 9. Heart failure: Class III/IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system. 10.Hypertension: Poorly controlled hypertension, whether due to inadequate treatment, or lack of treatment, is defined as follows:
- DBP >100 mmHg or SBP>160 mmHg for subjects taking hypertension medication(s) before screening and dialysis, if required.
- DBP >105 mmHg or SBP>170 mmHg for subjects who are asked to hold hypertension medication(s) before screening and dialysis. 11. Thrombotic Disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention), or other thrombosis related condition except shunt thrombosis) within the prior 6 months. 12. Pulmonary hypertension: Known pulmonary hypertension and those at higher risk (than normally associated with CKD) for pre-existing elevation in pulmonary pressure (e.g., significant heart failure or lung disease requiring supplemental oxygen, or those with connective tissue diseases). 13.Inflammatory disease: Chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease). 14. Haematological disease: Any haematological disease including those affecting platelets, the coagulation disorders (e.g., Protein C or S deficiency) or red blood cells (e.g. sickle cell anemia, myelodysplastic syndromes, haematological malignancy, myeloma, haemolytic anemia) or any other cause of anemia other than renal disease. 15. Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [alkaline phosphatase, alanine transaminase (ALT) or aspartate transaminase (AST) > 2.0 x upper limit of normal (ULN) or total bilirubin > 1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study. 16. Major surgery: (excluding vascular access surgery) Within the prior 12 weeks or planned during the study. 17. Transfusion: Blood transfusion within the prior 12 weeks or an anticipated need for blood transfusion during the study. 18. Ulcer and Active GI Bleeding: Evidence of active peptic, duodenal, or esophageal ulcer disease OR GI bleeding within the prior 12 weeks. 19. Acute infection: Clinical evidence of acute infection or history of infection requiring intravenous (IV) antibiotic therapy the eight weeks prior to Screening through Day 1 (randomization). 20. Malignancy: History of malignancy within the prior 5 years or are receiving treatment for cancer or those with a strong family history of cancer (e.g., familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated. 21. Eyes: History of proliferative retinopathy requiring treatment within the prior 12 months or macular edema requiring treatment. 22. Severe reactions: History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product. 23. Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Screening until the Follow-up Visit. 24. Androgens: New androgen therapy or changes to pre-existing androgen regimen within the prior 12 weeks. 25. Prior investigational product exposure: The Subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days. 26. Protocol compliance: Unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol. 27. Other Conditions: Any condition which in the investigator’s opinion should exclude the subject from participating in the study. 28. Pregnancy or Lactation: Pregnant females as determined by positive serum hCG test OR women who are lactating at Screening or during the trial.
Trial location(s)
Location
GSK Investigational Site
Arlington, Texas, United States, 76011
Status
Study Complete
Location
GSK Investigational Site
Arvada, Colorado, United States, 80002
Status
Study Complete
Location
GSK Investigational Site
Azusa, California, United States, 91702
Status
Study Complete
Location
GSK Investigational Site
Brooklyn, New York, United States, 11212
Status
Study Complete
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
Status
Study Complete
Location
GSK Investigational Site
Coral Springs, Florida, United States, 33071
Status
Study Complete
Location
GSK Investigational Site
Demmin, Mecklenburg-Vorpommern, Germany, 17109
Status
Study Complete
Location
GSK Investigational Site
Detroit, Michigan, United States, 48236
Status
Study Complete
Location
GSK Investigational Site
Durham, North Carolina, United States, 27704
Status
Study Complete
Location
GSK Investigational Site
Greenville, Texas, United States, 75402
Status
Study Complete
Location
GSK Investigational Site
Gurnee, Illinois, United States, 60031
Status
Study Complete
Location
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69120
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
Status
Study Complete
Location
GSK Investigational Site
Loa Angeles, California, United States, 90025-4837
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90022
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90057
Status
Study Complete
Location
GSK Investigational Site
Lynwood, California, United States, 60262
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73116
Status
Study Complete
Location
GSK Investigational Site
Pembroke Pines, Florida, United States, 33028
Status
Study Complete
Location
GSK Investigational Site
Pine Bluff, Arkansas, United States, 71603
Status
Study Complete
Location
GSK Investigational Site
Riverside, California, United States, 92505
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Study Complete
Location
GSK Investigational Site
Southgate, Michigan, United States, 48195
Status
Study Complete
Location
GSK Investigational Site
Spring Hill, Florida, United States, 34608
Status
Study Complete
Location
GSK Investigational Site
Waterbury, Connecticut, United States, 06708
Status
Study Complete
Location
GSK Investigational Site
West Hills, California, United States, 91307
Status
Study Complete
Location
GSK Investigational Site
Westminster, Colorado, United States, 80031
Status
Study Complete
Location
GSK Investigational Site
Whittier, California, United States, 90603
Status
Study Complete
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2013-27-05
Actual study completion date
2013-27-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website